{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:52:11Z","timestamp":1790949131628,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115489","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T21:20:07Z","timestamp":1746739207000},"page":"115489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3870-142X","authenticated-orcid":false,"given":"Chiara","family":"Dauccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alice Franzoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8461-7256","authenticated-orcid":false,"given":"Samuel","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Agbor-Tarh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-8188","authenticated-orcid":false,"given":"Shona","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Bines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-4958","authenticated-orcid":false,"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Di Cosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Vaz-Luis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Meglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-5841","authenticated-orcid":false,"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gombos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5223-5579","authenticated-orcid":false,"given":"Christine","family":"Desmedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Jerusalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Reaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeus","family":"Pienkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-7511","authenticated-orcid":false,"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro de","family":"Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2025.115489_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.ejca.2025.115489_bib2","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ejca.2025.115489_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2025.115489_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2025.115489_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djab023","article-title":"Association of obesity with breast cancer outcome in relation to cancer subtypes: a meta-analysis","volume":"113","author":"Lohmann","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejca.2025.115489_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-020-01356-w","article-title":"Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial","volume":"22","author":"Di Cosimo","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2025.115489_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2020.7606","article-title":"Body mass index and weight change in patients with HER2-positive early breast cancer: exploratory analysis of the ALTTOBIG 2-06 trial","volume":"19","author":"Martel","year":"2021","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"issue":"13","key":"10.1016\/j.ejca.2025.115489_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115489_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115489_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY Trial: 6 Years\u2019 Follow-Up","volume":"39","author":"Piccart","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115489_bib11","unstructured":"WHO: Global database on Body Mass Index. https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/topic-details\/GHO\/body-mass-index."},{"issue":"12","key":"10.1016\/j.ejca.2025.115489_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv275","article-title":"Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis","volume":"107","author":"Playdon","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ejca.2025.115489_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115489_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3520","article-title":"Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis","volume":"4","author":"Petrelli","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ejca.2025.115489_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-009-0512-0","article-title":"The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial","volume":"119","author":"De Azambuja","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"10.1016\/j.ejca.2025.115489_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2013.07.016","article-title":"Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients","volume":"49","author":"Mazzarella","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115489_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211006960","article-title":"Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients","volume":"13","author":"Ligorio","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115489_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-021-00241-9","article-title":"The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data","volume":"7","author":"Modi","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.115489_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx152","article-title":"Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials","volume":"28","author":"Yerushalmi","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115489_bib20","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.EPI-15-0334-T","article-title":"Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG oncology\/NSABP B-30, B-31, B-34, and B-38","volume":"25","author":"Cecchini","year":"2016","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"13","key":"10.1016\/j.ejca.2025.115489_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.28051","article-title":"Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831","volume":"119","author":"Crozier","year":"2013","journal-title":"Cancer"},{"issue":"15_","key":"10.1016\/j.ejca.2025.115489_bib22","article-title":"Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+\u2009breast cancer (BC): Biomarker analysis of the APHINITY trial","volume":"37","author":"Krop","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115489_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.05.003","article-title":"Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+\u2009T cells in tumors","volume":"54","author":"Xu","year":"2021","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ejca.2025.115489_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.08.004","article-title":"Enhancing CD8+\u2009T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy","volume":"32","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"issue":"35","key":"10.1016\/j.ejca.2025.115489_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00443","article-title":"Incidence of late relapses in patients with HER2-positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (Alliance) and NRG oncology\/NSABP B-31","volume":"37","author":"Chumsri","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115489_bib26","doi-asserted-by":"crossref","DOI":"10.1007\/s10147-022-02115-x","article-title":"The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study","volume":"27","author":"Han","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115489_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37780","article-title":"Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors","volume":"6","author":"Harborg","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"21","key":"10.1016\/j.ejca.2025.115489_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.27.2021","article-title":"Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial","volume":"28","author":"Sestak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2025.115489_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"30","author":"Griggs","year":"2012","journal-title":"J Clin Oncol"},{"issue":".1","key":"10.1016\/j.ejca.2025.115489_bib30","article-title":"The impact of chemotherapy dose density and dose intensity on breast cancer outcomewhat have we learned?","volume":"36","author":"Piccart","year":"2000","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2025.115489_bib31","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer \u2014 the results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2025.115489_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/193229680800200623","article-title":"Body composition methods: Comparisons and interpretation","volume":"2","author":"Duren","year":"2008","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115489_bib33","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-014-2843-8","article-title":"Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients","volume":"144","author":"Wong","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.ejca.2025.115489_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1988.6.8.1321","article-title":"Doxorubicin clearance in the obese","volume":"6","author":"Rodvold","year":"1988","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115489_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-018-5014-5","article-title":"Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I\u2013IIIB breast cancer receiving chemotherapy","volume":"173","author":"van den Berg","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ejca.2025.115489_bib36","article-title":"Body composition, adherence to anthracycline and taxane-based chemotherapy, and survival after nonmetastatic breast cancer","volume":"6","author":"Feliciano","year":"2020","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2025.115489_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.00471","article-title":"Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO Guideline update","volume":"39","author":"Griggs","year":"2021","journal-title":"J Clin Oncol"},{"issue":"39","key":"10.1016\/j.ejca.2025.115489_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_237423","article-title":"Weight management and physical activity for breast cancer prevention and control","author":"Ligibel","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4_ement","key":"10.1016\/j.ejca.2025.115489_bib39","article-title":"Abstract GS5-03: lifestyle intervention and effect on disease-free survival in early breast cancer pts: interim analysis from the randomized SUCCESS C study","volume":"79","author":"Janni","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115489_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/oby.23287","article-title":"The breast cancer weight loss trial (Alliance A011401): a description and evidence for the lifestyle intervention","volume":"30","author":"Delahanty","year":"2022","journal-title":"Obesity"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T20:03:14Z","timestamp":1748894594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"alternative-id":["S0959804925002709"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115489","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115489"}}